Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4787163
Max Phase: Preclinical
Molecular Formula: C32H53N11O7
Molecular Weight: 703.85
Molecule Type: Unknown
Associated Items:
ID: ALA4787163
Max Phase: Preclinical
Molecular Formula: C32H53N11O7
Molecular Weight: 703.85
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)O
Standard InChI: InChI=1S/C32H53N11O7/c1-18(2)16-24(30(49)50)42-27(46)23(17-19-9-11-20(44)12-10-19)41-28(47)25-8-5-15-43(25)29(48)22(7-4-14-39-32(36)37)40-26(45)21(33)6-3-13-38-31(34)35/h9-12,18,21-25,44H,3-8,13-17,33H2,1-2H3,(H,40,45)(H,41,47)(H,42,46)(H,49,50)(H4,34,35,38)(H4,36,37,39)/t21-,22-,23-,24-,25-/m0/s1
Standard InChI Key: FFSLONNNXGGUFO-KEOOTSPTSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 703.85 | Molecular Weight (Monoisotopic): 703.4129 | AlogP: -1.64 | #Rotatable Bonds: 20 |
Polar Surface Area: 314.96 | Molecular Species: ZWITTERION | HBA: 9 | HBD: 12 |
#RO5 Violations: 2 | HBA (Lipinski): 18 | HBD (Lipinski): 15 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.77 | CX Basic pKa: 11.82 | CX LogP: -5.50 | CX LogD: -6.23 |
Aromatic Rings: 1 | Heavy Atoms: 50 | QED Weighted: 0.04 | Np Likeness Score: 0.15 |
1. Chartier M,Desgagné M,Sousbie M,Côté J,Longpré JM,Marsault E,Sarret P. (2021) Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic., 64 (4.0): [PMID:33538583] [10.1021/acs.jmedchem.0c01726] |
Source(1):